Home » Stocks » SNGX

Soligenix, Inc. (SNGX)

Stock Price: $1.65 USD -0.03 (-1.79%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $1.69 +0.04 (2.42%) Feb 26, 7:59 PM
Market Cap 51.95M
Revenue (ttm) 2.72M
Net Income (ttm) -15.02M
Shares Out 29.57M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $1.65
Previous Close $1.68
Change ($) -0.03
Change (%) -1.79%
Day's Open 1.65
Day's Range 1.57 - 1.71
Day's Volume 1,291,044
52-Week Range 1.21 - 3.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Newsfile Corp - 4 days ago

New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commerc...

PRNewsWire - 3 weeks ago

PRINCETON, N.J., Feb. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 25, 2021) - PCG Digital: Advancing health care innovation is a cornerstone of thorough public health policy. Researching and developing new treatm...

PRNewsWire - 1 month ago

PRINCETON, N.J., Jan. 19, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...

PRNewsWire - 1 month ago

PRINCETON, N.J., Jan. 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...

PRNewsWire - 1 month ago

PRINCETON, N.J., Dec. 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...

PRNewsWire - 2 months ago

PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - December 9, 2020) -  The COVID-19 pandemic has been one of the most significant "black swan" events in recent history. As of early December 2020, around 1...

PRNewsWire - 3 months ago

PRINCETON, N.J., Nov. 12, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...

PRNewsWire - 3 months ago

PRINCETON, N.J., Nov. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...

Seeking Alpha - 4 months ago

Positive Phase 3 data reported on Oct. 22, solidifies the approvability of SGX301 for CTCL treatment, an estimated $250M annual revenue opportunity, yet SNGX's valuation is only ~$55M. SGX942 ...

PRNewsWire - 4 months ago

PRINCETON, N.J., Oct. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...

PRNewsWire - 5 months ago

PRINCETON, N.J., Sept. 15, 2020 /PRNewswire/ -- Soligenix, Inc.

PRNewsWire - 5 months ago

PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ -- Soligenix, Inc.

PRNewsWire - 5 months ago

PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc.

PRNewsWire - 6 months ago

PRINCETON, N.J., Aug. 27, 2020 /PRNewswire/ -- Soligenix, Inc.

PRNewsWire - 6 months ago

PRINCETON, N.J., Aug. 14, 2020 /PRNewswire/ -- Soligenix, Inc.

Seeking Alpha - 6 months ago

Soligenix: Multiple Shots On Goal, Strong Evidence Of Success, And Attractive Valuation

PRNewsWire - 7 months ago

PRINCETON, N.J., July 20, 2020 /PRNewswire/ -- Soligenix, Inc.

Benzinga - 8 months ago

Soligenix (NASDAQ: SNGX) shares were trading higher on Friday after the company completed enrollment in its Phase 3 clinical trial of SGX942 for the treatment of oral mucositis.

PRNewsWire - 8 months ago

PRINCETON, N.J., June 22, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...

PRNewsWire - 8 months ago

PRINCETON, N.J., June 9, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...

PRNewsWire - 9 months ago

PRINCETON, N.J., May 15, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...

Seeking Alpha - 10 months ago

Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade Opportunity

Benzinga - 10 months ago

Shares of rare disease biopharma Soligenix, Inc. (NASDAQ: SNGX) were spiking higher Thursday after the company announced a coronavirus-related licensing agreement.

Seeking Alpha - 1 year ago

Soligenix: Two Phase-3 Clinical Trials - Results By June 2020

Seeking Alpha - 1 year ago

Soligenix is a small biotech company with just ~$20M market cap.

About SNGX

Soligenix, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also... [Read more...]

Industry
Biotechnology
IPO Date
Jun 15, 1987
CEO
Christopher Schaber
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
SNGX
Full Company Profile

Financial Performance

In 2019, Soligenix's revenue was $4.63 million, a decrease of -11.67% compared to the previous year's $5.24 million. Losses were -$9.36 million, 5.12% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Soligenix stock is "Buy." The 12-month stock price forecast is 3.85, which is an increase of 133.33% from the latest price.

Price Target
$3.85
(133.33% upside)
Analyst Consensus: Buy